AR031563A1 - Una composicion farmaceutica para emplear en el tratamiento de trastornos menopausicos o posmenopausicos de estrogenos y acetato de medroxiprogesterona, una unidad de dosificacion farmaceutica y uso de una combinacion de estrogenos conjugados y acetato de medroxiprogesterona para la manufactura de u - Google Patents
Una composicion farmaceutica para emplear en el tratamiento de trastornos menopausicos o posmenopausicos de estrogenos y acetato de medroxiprogesterona, una unidad de dosificacion farmaceutica y uso de una combinacion de estrogenos conjugados y acetato de medroxiprogesterona para la manufactura de uInfo
- Publication number
- AR031563A1 AR031563A1 ARP010101273A ARP010101273A AR031563A1 AR 031563 A1 AR031563 A1 AR 031563A1 AR P010101273 A ARP010101273 A AR P010101273A AR P010101273 A ARP010101273 A AR P010101273A AR 031563 A1 AR031563 A1 AR 031563A1
- Authority
- AR
- Argentina
- Prior art keywords
- conjugated
- treatment
- combination
- acetate
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
Abstract
Una composicion farmacéutica para emplear en el tratamiento de trastornos menopáusicos o posmenopáusicos que comprende estrogenos conjugados, una dosis de aproximadamente 1,5 mg de acetato de medroxiprogesterona y un vehículo farmacéutico, que ofrezcan una terapia hormonal sustitutiva a pacientes en estado perimenopáusicos, menopáusico y posmenopáusico a través de la administracion continua de combinaciones de estrogenos conjugados y acetatos de medroxiprogesteronas. Se describen además una unidad de dosificacion farmacéutica y uso de combinacion de estrogenos conjugados y acetato de medroxiprogesterona para la manufactura de un medicamento.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19063000P | 2000-03-20 | 2000-03-20 | |
US26860701P | 2001-02-14 | 2001-02-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR031563A1 true AR031563A1 (es) | 2003-09-24 |
Family
ID=26886279
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP010101273A AR031563A1 (es) | 2000-03-20 | 2001-03-19 | Una composicion farmaceutica para emplear en el tratamiento de trastornos menopausicos o posmenopausicos de estrogenos y acetato de medroxiprogesterona, una unidad de dosificacion farmaceutica y uso de una combinacion de estrogenos conjugados y acetato de medroxiprogesterona para la manufactura de u |
Country Status (30)
Country | Link |
---|---|
US (2) | US20010034340A1 (es) |
EP (1) | EP1265616B1 (es) |
JP (1) | JP2003527416A (es) |
KR (1) | KR100805648B1 (es) |
CN (1) | CN1239160C (es) |
AR (1) | AR031563A1 (es) |
AT (1) | ATE326227T1 (es) |
AU (2) | AU5003401A (es) |
BG (1) | BG66075B1 (es) |
BR (1) | BR0109334A (es) |
CA (1) | CA2402983A1 (es) |
CY (1) | CY1105632T1 (es) |
CZ (1) | CZ20023162A3 (es) |
DE (1) | DE60119703T2 (es) |
DK (1) | DK1265616T3 (es) |
EA (1) | EA005592B1 (es) |
EE (1) | EE05129B1 (es) |
ES (1) | ES2261393T3 (es) |
HK (1) | HK1049449B (es) |
HR (1) | HRP20020837B1 (es) |
HU (1) | HUP0302093A3 (es) |
IL (1) | IL151512A0 (es) |
MX (1) | MXPA02009116A (es) |
NO (1) | NO326886B1 (es) |
NZ (1) | NZ521171A (es) |
PL (1) | PL201762B1 (es) |
PT (1) | PT1265616E (es) |
SK (1) | SK286169B6 (es) |
TW (1) | TWI271194B (es) |
WO (1) | WO2001070208A2 (es) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010044431A1 (en) * | 2000-03-21 | 2001-11-22 | Rodriguez Gustavo C. | Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium |
US6245819B1 (en) | 2000-07-21 | 2001-06-12 | Hormos Medical Oy, Ltd. | Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause |
EP1857110A3 (en) * | 2001-03-16 | 2008-08-06 | Wyeth | Hormone replacement therapy |
US20020169150A1 (en) * | 2001-03-16 | 2002-11-14 | Wyeth | Hormone replacement therapy |
US20130203722A1 (en) | 2006-09-26 | 2013-08-08 | Rhonda R. Voskuhl | Estriol therapy for autoimmune and neurodegenerative disease and disorders |
TWI252111B (en) * | 2001-12-14 | 2006-04-01 | Solvay Pharm Gmbh | Matrix film tablet with controlled release of a natural mixture of conjugated estrogens |
TW200306196A (en) * | 2002-04-03 | 2003-11-16 | Wyeth Corp | Hormone replacement therapy |
TW200306846A (en) * | 2002-04-03 | 2003-12-01 | Wyeth Corp | Hormone replacement therapy |
AU2003210759B2 (en) * | 2002-04-03 | 2007-01-25 | Barr Laboratories, Inc. | Step-down estrogen therapy |
TW200306851A (en) * | 2002-04-29 | 2003-12-01 | Wyeth Corp | Hormone replacement therapy |
TW200400040A (en) * | 2002-05-17 | 2004-01-01 | Wyeth Corp | Hormone replacement therapy |
PT1509215E (pt) * | 2002-06-06 | 2007-01-31 | Hormos Medical Ltd | Tratamento ou profilaxia da atrofia urogenital e seus sintomas em mulheres |
TW200407124A (en) * | 2002-06-25 | 2004-05-16 | Wyeth Corp | Use of thio-oxindole derivatives in treatment of hormone-related conditions |
AU2003247608A1 (en) * | 2002-06-25 | 2004-01-06 | Wyeth | Use of cyclothiocarbamate derivatives in treatment of hormone-related conditions |
US8349819B2 (en) | 2002-10-09 | 2013-01-08 | Dr. Reddy's Laboratories New York, Inc. | Steroid extraction process from urine sources |
EP1622623A4 (en) * | 2003-04-11 | 2009-03-18 | Barr Lab Inc | METHOD FOR THE ADMINISTRATION OF ESTROGENIC AND TESTED |
US20060040904A1 (en) * | 2004-08-17 | 2006-02-23 | Ahmed Salah U | Vaginal cream compositions, kits thereof and methods of using thereof |
WO2007076144A2 (en) | 2005-12-27 | 2007-07-05 | Duramed Pharmaceuticals, Inc. | Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof |
CA2644913A1 (en) * | 2006-04-05 | 2007-10-18 | Wyeth | Methods for prevention and treatment of conditions arising from local estrogen deficiency |
CL2007003429A1 (es) * | 2006-11-29 | 2008-04-11 | Wyeth Corp | Tableta bi-capa que comprende una primera capa con al menos un estrogeno y una segunda capa con uno o mas agentes terapeuticos seleccionados entre un modulador selectivo del receptor de estrogeno y un agente progestacional; proceso de produccion, uti |
WO2008099060A2 (en) * | 2007-02-14 | 2008-08-21 | Hormos Medical Ltd | Methods for the preparation of fispemifene from ospemifene |
EP2821385B1 (en) * | 2007-02-14 | 2016-07-27 | Hormos Medical Ltd. | Method for the preparation of therapeutically valuable triphenylbutene derivatives |
EP2164498A4 (en) | 2007-06-04 | 2010-09-08 | Univ California | PREGNANCY HORMONE ASSOCIATION FOR THE TREATMENT OF AUTOIMMUNE DISEASES |
KR100989093B1 (ko) | 2008-01-18 | 2010-10-25 | 한화제약주식회사 | 생강나무 가지의 추출물을 포함하는 심혈관계 질환의 예방 및 치료용 조성물 |
US9734496B2 (en) | 2009-05-29 | 2017-08-15 | Paypal, Inc. | Trusted remote attestation agent (TRAA) |
EP3689364A1 (en) * | 2010-02-08 | 2020-08-05 | Shenzhen Evergreen Therapeutics Co., Ltd. | Methods for the use of progestogen as a glucocorticoid sensitizer |
RS62297B1 (sr) | 2011-11-23 | 2021-09-30 | Therapeuticsmd Inc | Prirodne kombinovane hormonske supstitucione formulacije i terapije |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US9321712B2 (en) | 2012-10-19 | 2016-04-26 | Fermion Oy | Process for the preparation of ospemifene |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11224603B2 (en) * | 2013-12-13 | 2022-01-18 | Requis Pharmaceuticals, Inc. | Antihistamines in combination with a range of substances for improved health |
WO2015168002A1 (en) | 2014-04-28 | 2015-11-05 | The Regents Of The University Of California | Pharmaceutical packaging for estriol therapy |
US10799512B2 (en) | 2014-04-28 | 2020-10-13 | The Regents Of The University Of California | Estrogen combination for treatment of multiple sclerosis |
JP2017516768A (ja) | 2014-05-22 | 2017-06-22 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | 天然の併用ホルモン補充療法剤及び療法 |
WO2016036719A1 (en) | 2014-09-02 | 2016-03-10 | The Regents Of The University Of California | Estrogen therapy for brain gray matter atrophy and associated disability |
US9962395B2 (en) | 2014-09-29 | 2018-05-08 | The Regents Of The University Of California | Compositions and methods for maintaining cognitive function |
EP3277285A4 (en) | 2015-03-30 | 2018-12-19 | The Regents of the University of California | Methods of monitoring estriol therapy |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
RU2018133932A (ru) | 2016-04-01 | 2020-05-12 | Терапьютиксмд, Инк. | Фармацевтическая композиция стероидного гормона |
WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
US20210386757A1 (en) * | 2018-10-17 | 2021-12-16 | Sarah S. Stadler | Methods of Treating Menopausal Symptoms Using Low Dose Progesterone |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU582540B2 (en) * | 1983-08-05 | 1989-04-06 | Pre Jay Holdings Ltd. | A method of hormonal treatment of perimenopausal, menopausal and post-menopausal disorders and multi-preparation pack therefor |
US4826831A (en) * | 1983-08-05 | 1989-05-02 | Pre Jay Holdings Limited | Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens |
FI101601B (fi) * | 1987-09-24 | 1998-07-31 | Jencap Res Ltd | Ehkäisyvalmiste sekä estrogeenin ja progestiinin käyttö ehkäisyvalmist een valmistusmenetelmässä |
NL9301562A (nl) * | 1993-09-09 | 1995-04-03 | Saturnus Ag | Preparaat voor substitutietherapie. |
US5554601A (en) * | 1993-11-05 | 1996-09-10 | University Of Florida | Methods for neuroprotection |
US5759577A (en) * | 1995-01-17 | 1998-06-02 | American Home Products Corporation | Controlled release of steroids from sugar coatings |
US5547948A (en) * | 1995-01-17 | 1996-08-20 | American Home Products Corporation | Controlled release of steroids from sugar coatings |
-
2001
- 2001-03-15 US US09/808,878 patent/US20010034340A1/en not_active Abandoned
- 2001-03-16 IL IL15151201A patent/IL151512A0/xx not_active IP Right Cessation
- 2001-03-16 KR KR1020027012420A patent/KR100805648B1/ko not_active IP Right Cessation
- 2001-03-16 EA EA200201000A patent/EA005592B1/ru not_active IP Right Cessation
- 2001-03-16 ES ES01923331T patent/ES2261393T3/es not_active Expired - Lifetime
- 2001-03-16 DE DE60119703T patent/DE60119703T2/de not_active Expired - Lifetime
- 2001-03-16 CN CNB018068235A patent/CN1239160C/zh not_active Expired - Fee Related
- 2001-03-16 MX MXPA02009116A patent/MXPA02009116A/es active IP Right Grant
- 2001-03-16 EE EEP200200535A patent/EE05129B1/xx not_active IP Right Cessation
- 2001-03-16 PT PT01923331T patent/PT1265616E/pt unknown
- 2001-03-16 PL PL363157A patent/PL201762B1/pl not_active IP Right Cessation
- 2001-03-16 BR BR0109334-7A patent/BR0109334A/pt not_active Application Discontinuation
- 2001-03-16 DK DK01923331T patent/DK1265616T3/da active
- 2001-03-16 WO PCT/US2001/040302 patent/WO2001070208A2/en active IP Right Grant
- 2001-03-16 AU AU5003401A patent/AU5003401A/xx active Pending
- 2001-03-16 HU HU0302093A patent/HUP0302093A3/hu unknown
- 2001-03-16 EP EP01923331A patent/EP1265616B1/en not_active Expired - Lifetime
- 2001-03-16 NZ NZ521171A patent/NZ521171A/en not_active IP Right Cessation
- 2001-03-16 CZ CZ20023162A patent/CZ20023162A3/cs unknown
- 2001-03-16 AU AU2001250034A patent/AU2001250034B2/en not_active Ceased
- 2001-03-16 AT AT01923331T patent/ATE326227T1/de active
- 2001-03-16 CA CA002402983A patent/CA2402983A1/en not_active Abandoned
- 2001-03-16 JP JP2001568406A patent/JP2003527416A/ja active Pending
- 2001-03-16 SK SK1348-2002A patent/SK286169B6/sk not_active IP Right Cessation
- 2001-03-19 TW TW090106349A patent/TWI271194B/zh not_active IP Right Cessation
- 2001-03-19 AR ARP010101273A patent/AR031563A1/es unknown
-
2002
- 2002-09-12 BG BG107095A patent/BG66075B1/xx unknown
- 2002-09-19 NO NO20024478A patent/NO326886B1/no not_active IP Right Cessation
- 2002-10-18 HR HR20020837A patent/HRP20020837B1/xx not_active IP Right Cessation
-
2003
- 2003-03-06 HK HK03101651.5A patent/HK1049449B/zh not_active IP Right Cessation
-
2006
- 2006-07-03 CY CY20061100910T patent/CY1105632T1/el unknown
-
2007
- 2007-11-06 US US11/979,633 patent/US20090005351A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR031563A1 (es) | Una composicion farmaceutica para emplear en el tratamiento de trastornos menopausicos o posmenopausicos de estrogenos y acetato de medroxiprogesterona, una unidad de dosificacion farmaceutica y uso de una combinacion de estrogenos conjugados y acetato de medroxiprogesterona para la manufactura de u | |
HUP0204291A2 (hu) | Hormonpótlási terápiához alkalmazható készítmény, amely drospirenont és ösztrogént tartalmaz | |
NO982815L (no) | Ultralav dose orale preventiver med mindre menstrasjonsbl°dning og vedvarende virkningsfullhet | |
NZ516502A (en) | Administration of non-oral androgenic steroids to women having an elevated level of sex hormone binding globulin (SHBG) | |
AR033042A1 (es) | Terapia de reemplazo hormonal | |
AR049112A1 (es) | Composiciones, metodos y kit, para el tratamiento de trastorno disforico premenstrual | |
BR9709934A (pt) | Kit de terapia de reposição hormonal e/ou contraceptivo uso de unidades de dosagem diária consistindo essecialmente de um progestogênio e processo de preparação de um sistema de liberação de droga | |
CO5261567A1 (es) | Uso de sulfamatos estrogenos biogenicos en una terapia de reemplazo de hormonas | |
AR035946A1 (es) | Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos | |
KR970706004A (ko) | 호르몬 약물 및 에스트로겐 결핍을 치유하기 위한 그의 용도(novel hormonal medicaments and use thereof for correcting oestrogen deficiencies) | |
MY128482A (en) | New hormonal composition and its use | |
HRP20090256T1 (en) | Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method | |
AR049195A1 (es) | Uso de una combinacion de etinilestradiol y acetato de clormadinona para la preparacion de un medicamento | |
HUP0101005A2 (hu) | Szteroid aromatáz gátlót tartalmazó gyógyszer emlőrák megelőzésére és/vagy kezelésére | |
PT889727E (pt) | Combinacao sequencial estrogenio/ antagonista da progesterona para terapia hormonal de substituicao | |
AU729898B2 (en) | Transdermal therapeutic system having an active compound combination comprising oestriol | |
Brackman | OESCLIM®: summary of tolerability and safety | |
TH27339A (th) | ฮอร์โมนตัวใหม่ที่ใช้เป็นยาและประโยชน์ของมันในการรักษาภาวะขาดเอสโตเจน | |
AR033260A1 (es) | Nueva composicion hormonal y su utilizacion | |
CO5280075A1 (es) | Drospirenona para terapia de reemplazo de hormonas | |
AU3662300A (en) | Use of sex hormones to obtain a nasal pharmaceutical composition that is useful in the treatment of undesirable uterine bleeding | |
MXPA99001793A (es) | Sistema terapeutico percutaneo, con una combinacion de sustancia activa que contiene estriol | |
Panay et al. | Pulsed estrogen therapy: a new concept in hormone replacement therapy | |
AR043470A2 (es) | Una composicion farmaceutica para ser usada como anticonceptivo | |
TH134365B (th) | โดรสไพริโนนสำหรับการรักษาด้วยการแทนที่ฮอร์โมน |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |